Please login to the form below
tafamidis
This page shows the latest tafamidis news and features for those working in and with pharma, biotech and healthcare.
Alnylam gets EU nod for Onpattro amid pricing backlash
s Vyndaqel (tafamidis) has been registered in Europe since 2011 and costs in the region of $13, 000 per month. ... for tafamidis as a treatment for cardiomyopathy associated with hATTR amyloidosis after reporting positive results in the phase III
Latest news
-
Alnylam claims RNAi milestone with Onpattro approval
approved for that indication by the EMA in July and Pfizer’s Vyndaqel (tafamidis) which has been on the market since 2011 but was rejected by the FDA in 2012.
-
Alnylam’s amyloidosis drug heads latest crop of CHMP approvals
The EMA said in a statement that having two drugs “considerably widens” the therapeutic options for hATTR amyloidosis, which include liver transplant, Pfizer’s Vyndaqel (tafamidis) and off-label non-steroidal
-
Pfizer drug gets speedy FDA review for rare heart failure complication
The average life expectancy for people with transthyretin cardiomyopathy is three to five years from diagnosis, says Pfizer, which also got fast-track status for tafamidis last year. ... Since then, tafamidis has also been approved in other markets
-
Pfizer’s flat sales focus investor attention on M&A
Vaccines for Clostridium difficile and staphylococcal infections and a new-generation Prevnar are making progress, along with rare disease therapies tafamidis for neuropathies and rivipansel for vaso-occlusive crises and tanezumab
-
Pfizer gets EU approval for neurodegenerative disease drug
worldwide. Vyndaqel (tafamidis; formerly Fx-1006A) becomes the first treatment approved anywhere in the world to treat the disease.
More from news
Approximately 1 fully matching, plus 8 partially matching documents found.
Latest Intelligence
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
produced impressive data for its Vyndaqel (tafamidis). ... Onpattro looked to have the edge in terms of clinical data, but Pfizer has new data showing tafamidis is effective in treating patients with cardiomyopathy – the heart damage caused by the
-
Tough times for pharma in Portugal
spondylitis. For instance, the Portuguese Association of Amyloidosis (APP) is petitioning parliament for access to Pfyzer's Vyndaqel (tafamidis).
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
- Freelance Senior Account Manager / Account Director - Healthcare...
-
£350-400 depending on experience
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Freelance AM/ AD Healthcare Advertising
-
£350-400 depending on experience
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Digital Account Director
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Associate Director – Social Healthcare – London
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
-
Account Director, Medical Education
-
Salary TBC
-
Health Consultant - Brand Comms
-
Competitive Salary
- Scientific Director – Medical Communications
-
Salary TBC
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Senior Account Manager, Medical Communications, London
-
Excellent package
- Home-based Senior Medical Writer – Med Ed
-
Salary TBC
Subscribe to our email news alerts
- Where next in Alzheimer’s disease R&D?
- McCann Health bolsters European leadership team
- Biogen and Eisai pull plug on Alzheimer’s drug
- Novo uses voucher for speedy answer on oral semaglutide
- Is Orkambi deal close? Vertex meets again today with NHS England
- Amgen, Servier heart failure drug clears trial hurdle
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Where next in Alzheimer’s disease R&D?
- How past failures and emerging biology are reshaping drug development...
- Brain power: fresh approaches to Alzheimer’s drug discovery
- New alliances are learning from past mistakes and breaking down research barriers...
- Genomics integration: can the NHS rise to the challenge?
- Experts gather to discuss the UK’s genomic landscape...
Quick links
Infographics
